Meeting
2013 ASCO Annual Meeting
Prospective randomized phase II trial with gemcitabine versus gemcitabine plus sunitinib in advanced pancreatic cancer: A study of the CESAR Central European Society for Anticancer Drug Research-EWIV.
Authors
Heike Richly
West German Cancer Center, University Duisburg-Essen, Essen, Germany
Heike Richly , Luise Maute , Gerhard Heil , Jörn Rüssel , Elke Jäger , Dieter Koeberle , Stefan Fuxius , Karin Weigang-Koehler , Walter Aulitzky , Bernhard Woehrmann , Gernot Georg Hartung , Berta Moritz , Iris Burkholder , Max E. Scheulen , Lothar Bergmann
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Pancreatic Cancer
Clinical Trial Registration Number
NCT00673504
Citation
J Clin Oncol 31, 2013 (suppl; abstr 4035)
DOI
10.1200/jco.2013.31.15_suppl.4035
Abstract #
4035
Poster Bd #
15E
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Phase 2 Quilt 88 trial of DAMP inducers combined with IL15 superagonist, N-803, and anti–PD-L1 NK cell therapy more than doubles historical overall survival in patients with third- to sixth-line advanced pancreatic cancer.
First Author: Tara Elisabeth Seery
Poster
2021 Gastrointestinal Cancers Symposium
Efficacy and safety of 5-fluorouracil (5-FU) / levofolinate / irinotecan (FOLFIRI) for previously treated advanced pancreatic cancer (APC).
First Author: Hiromichi Shirasu
Poster
2020 ASCO Virtual Scientific Program
A multicenter randomized phase II study of nivolumab in combination with gemcitabine/cisplatin or ipilimumab as first-line therapy for patients with advanced unresectable biliary tract cancer (BilT-01).
First Author: Vaibhav Sahai
Poster
2020 ASCO Virtual Scientific Program
A randomized phase II study of second-line treatment with liposomal irinotecan, and S-1 versus liposomal irinotecan and 5-fluorouracil in gemcitabine-refractory metastatic pancreatic cancer patients.
First Author: Esther Pijnappel